Iterum Therapeutics plc Quarterly Operating Income (Loss) in USD from Q2 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Iterum Therapeutics plc quarterly/annual Operating Income (Loss) history and growth rate from Q2 2017 to Q3 2024.
  • Iterum Therapeutics plc Operating Income (Loss) for the quarter ending September 30, 2024 was -$4.89M, a 70.7% increase year-over-year.
  • Iterum Therapeutics plc Operating Income (Loss) for the twelve months ending September 30, 2024 was -$26.5M, a 39.8% increase year-over-year.
  • Iterum Therapeutics plc annual Operating Income (Loss) for 2023 was -$47.5M, a 56.2% decline from 2022.
  • Iterum Therapeutics plc annual Operating Income (Loss) for 2022 was -$30.4M, a 23.8% decline from 2021.
  • Iterum Therapeutics plc annual Operating Income (Loss) for 2021 was -$24.5M, a 23.6% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$26.5M -$4.89M +$11.8M +70.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$38.3M -$3.98M +$6.85M +63.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$45.1M -$6.16M +$2.37M +27.7% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$47.5M -$11.4M -$3.51M -44.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 -$44M -$16.7M -$9.65M -137% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$34.3M -$10.8M -$2.77M -34.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$31.5M -$8.53M -$1.16M -15.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$30.4M -$7.93M -$1.1M -16.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 -$29.3M -$7.03M -$2.16M -44.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$27.1M -$8.05M -$1.06M -15.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$26.1M -$7.37M -$1.53M -26.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$24.5M -$6.83M -$2.19M -47.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-28
Q3 2021 -$22.4M -$4.87M +$1.46M +23.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$23.8M -$6.99M +$1.27M +15.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$25.1M -$5.85M +$7.05M +54.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$32.1M -$4.64M +$18.5M +80% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-16
Q3 2020 -$50.7M -$6.34M +$24.7M +79.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$75.3M -$8.25M +$19.1M +69.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$94.4M -$12.9M +$7.57M +37% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$102M -$23.2M +$766K +3.2% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-28
Q3 2019 -$103M -$31M -$6.01M -24.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$96.8M -$27.4M -$12M -77.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$84.8M -$20.5M -$8.26M -67.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$76.6M -$23.9M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-12
Q3 2018 -$25M -$16.7M -201% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$15.4M -$9.01M -141% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$12.2M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q3 2017 -$8.3M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$6.41M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.